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Abstract
OBJECTIVE—To describe the effect of the mature 1-dose varicella vaccination program on 
varicella morbidity, we analyzed 2 national databases for varicella-related hospitalizations in the 
United States since implementation of the varicella vaccination program in 1995.
PATIENTS AND METHODS—Data from the National Hospital Discharge Survey and 
Nationwide Inpatient Sample were analyzed to describe trends in varicella-related hospitalizations 
during the 1-dose vaccination era (2000 –2006) compared with those in the prevaccination era 
(1988 –1995). Varicella-related hospitalizations were defined by using International Classification 
of Diseases, Ninth Revision codes. Results were extrapolated to represent national estimates.
RESULTS—Using National Hospital Discharge Survey data, 24 488 varicella-related 
hospitalizations were estimated to occur in the United States during the 1-dose vaccination era. 
The varicella-related hospitalization rate was 0.12 per 10 000 population during the 1-dose 
vaccination era versus 0.42 per 10 000 population in the prevaccination era (P < .01). During the 
1-dose vaccination era, the estimated annual average number of varicella-related hospitalizations 
was significantly lower and decreased by ≥65% in all age groups compared with those in the 
prevaccination era (P < .001 in all age groups). The varicella-related hospitalization rate during the 
1-dose vaccination era estimated from the Nationwide Inpatient Sample was 0.09 per 10 000 
population.
CONCLUSIONS—Varicella-related hospitalization numbers and rates declined significantly 
during the 1-dose varicella vaccination era. Assuming declines in varicella-related hospitalizations 
are due, mainly, to the routine childhood varicella vaccination program, these data suggest that 
varicella vaccination prevented ~50 000 varicella-related hospitalizations in the United States from 
2000 to 2006. Pediatrics 2011; 127:000
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The varicella vaccination program, implemented in 1995, has decreased varicella incidence 
and mortality in the United States.1–7 Data from active surveillance sites demonstrated a 
90% decline in varicella from 1995 to 2005.4 Data from passive surveillance from 4 states 
showed declines in varicella incidence ranging from 53% to 94% by 2005 compared with 
the prevaccination era.8 In a number of studies that examined the early impact of the 
varicella vaccination program on varicella hospitalizations, evidence of decline after vaccine 
implementation was found,2,6,9–13 although statistically significant declines were not 
reported in all studies.9,10
To further evaluate trends in varicella-related hospitalizations in the United States before the 
implementation of the routine 2-dose varicella vaccination program, we analyzed data from 
the National Hospital Discharge Survey (NHDS) from 1988 to 2006 and from the 
Nationwide Inpatient Sample (NIS) from 1998 to 2006 to calculate estimates of numbers 
and rates of varicella-related hospitalizations and to describe changes in the epidemiology of 
varicella-related hospitalizations after implementation of the varicella vaccination program.
PATIENTS AND METHODS
Data Sources
The NHDS is based on a nationally representative sample of inpatient discharge records 
from noninstitutional, nonfederal, short-stay hospitals. The NHDS has a 3-stage sampling 
design: stage 1 includes all US hospitals with 1000 or more beds; stage 2 includes a 
representative sample of other hospitals on the basis of size, specialty, and geographic 
location; and stage 3 includes a random sample of discharges from each of the hospitals. The 
discharge records are weighted according to hospital size and region to allow calculation of 
national estimates. From 1988 to 2006, NHDS collected data on hospitalizations from a 
nationally representative sample of ~500 hospitals that represent ~270 000 entries per year.14
The NIS, a component of the Healthcare Cost and Utilization Project, is sponsored by the 
Agency for Healthcare Research and Quality and is currently the largest inpatient care data 
set that is publicly available in the United States. The NIS is a nationally representative 
annual sample of discharges from all community hospitals, defined as nonfederal, short-
term, general, and other specialty hospitals.15 It is designed to approximate a 20% sample of 
US community hospitals stratified by hospital ownership/control, bed size, teaching status, 
urban/rural location, and US region. The NIS includes information on between 5 and 8 
million discharges per year from ~1000 hospitals. Discharge level weights are used to 
calculate national estimates of hospital discharges.15 We analyzed data from 1998, the first 
year when at least 20 states participated and the number of hospitals sampled neared 1000.
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The methodology for identifying varicella-related hospitalizations was the same as that 
described by Galil et al.9 Varicella-related hospitalizations were defined by using 
International Classification of Diseases, Ninth Revision, Clinical Modification codes 
(ICD-9) as follows: (1) varicella as the principal discharge code (052– 052.9); (2) 
postvaricella encephalitis (052.0) or varicella pneumonitis (052.1) in any diagnostic 
position; or (3) varicella in any diagnostic position in a person with a severe 
immunocompromising condition that would likely necessitate hospitalization for varicella 
[HIV infection, malignancy, severe defect of T cell immunity, organ transplant recipient, or 
chemotherapy recipient]; or (4) a well-described potential complication of varicella as the 
principal discharge diagnosis and a varicella code in any subsequent position. Fluid/
electrolyte disturbances were defined by using ICD-9 codes for the following conditions: 
volume depletion; hyposmolality; hyponatremia; hyperpotassemia; hypopotassemia; or other 
electrolyte and fluid disorders. Hospitalizations with an ICD-9 code for varicella that did not 
meet the above criteria were defined as incidental cases of varicella (eg, hospitalization 
during a varicella infection for a reason other than the varicella or varicella infection with 
onset during hospitalization for another reason). To address the possibility that our reliance 
on electronic coding to identify varicella-related hospitalizations could have resulted in the 
inadvertent inclusion of incidental varicella hospitalizations, we also calculated varicella-
related hospitalization rates by using a more restrictive case definition that was limited to 
hospitalizations in which varicella was listed as the principal discharge code. 
Hospitalizations with coexistent herpes zoster codes (053.xx) were excluded.
Patients were stratified by underlying health status into 3 mutually exclusive categories: (1) 
having no comorbid or immunocompromising condition; (2) having a comorbid condition 
(eg, diabetes or cardiac disease); or (3) immunocompromised (eg, HIV or cancer). Because 
NIS records include up to 15 diagnostic positions, we limited analysis to the first 7 ICD-9 
codes to maintain comparability with the NHDS data, which only contain 7 diagnostic 
positions.
We defined the prevaccination era as 1988 –1995, the period before licensure and 
widespread use of the varicella vaccine. The 1-dose vaccination era was defined as the years 
2000 to 2006, a period when 1-dose national varicella vaccination coverage was >65%16 and 
before implementation of the universal 2-dose vaccination recommendation.
Data Analysis
The varicella-related hospitalization numbers and rates we present are extrapolations to 
represent national estimates. Data from the US Census and the National Health Interview 
Survey were used as the denominators to calculate varicella-related hospitalization rates per 
10 000 population and per 10 000 varicella cases, respectively. Rates per 10 000 cases from 
the prevaccination era could not be compared with rates from the 1-dose vaccination era 
because of changes in methodology for collecting data on numbers of varicella cases in the 
National Health Interview Survey in 2000. Confidence intervals (CIs) for rates were 
calculated using the Taylor series linearization method to account for the complex survey 
designs.
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SUDAAN 10.0 (SAS Institute, Inc, Cary, NC) was used for analysis. Poisson regression 
method was used as a test for trend. Analyses of varicella-related complications were limited 
by sample size; estimates on the basis of unweighted sample sizes of <30 are considered 
unreliable and not reported.
RESULTS
NHDS
Estimated Number of Varicella Hospitalizations—On the basis of NHDS data, an 
estimated 34 774 hospitalizations with a varicella discharge diagnosis were identified in the 
United States during the 1-dose vaccination era (2000– 2006). Of these, 3052 (8.8%) 
hospitalizations were excluded because of coexisting herpes zoster codes and 7234 (20.8%) 
as incidental varicella cases, leaving 24 488 (70.4%) varicella-related hospitalizations. This 
corresponds to an estimated annual average of 3498 varicella-related hospitalizations [95% 
CI: 2447– 4549] during the 1-dose vaccination era, compared with 10 632 during the 
prevaccination era (P < .01). The estimated number of varicella-related hospitalizations in 
the United States during the 1-dose vaccination era varied from a peak of 4809 in 2000 to a 
low of 1718 in 2006 (P < .01). Of the 24 488 varicella-related hospitalizations, 20 387 
(83.2%) had varicella listed as the principal discharge code, which resulted in an average 
annual estimate of 2912 varicella-related hospitalizations, compared with an average annual 
estimate of 8680 during the prevaccination era, using this more restrictive definition (P < .
01).
Rates of Varicella Hospitalizations—The overall varicella-related hospitalization rate 
on the basis of NHDS data was 0.12 (95% CI: 0.08–0.16) per 10 000 population during the 
1-dose vaccination era versus 0.42 (95% CI: 0.33– 0.50) per 10 000 population in the 
prevaccination era (P < .01) (Fig 1). The overall varicella-related hospitalization rate per 10 
000 varicella cases was 23.1 during the 1-dose vaccination era and fluctuated annually (Fig 
1).
The estimated average annual varicella-related hospitalization rates on the basis of NHDS 
data decreased by >70% in all age groups younger than 20 and by 65% in the 20-and-older 
age group during the 1-dose vaccination era compared with the prevaccination era (P < .001 
for trend) (Fig 2). Although rates remained highest for the youngest age group (0–4 years), 
they were 72% lower than during the prevaccination era (P < .001 for trend) (Table 1). The 
proportions of hospitalizations by age group did not differ substantially when varicella-
related hospitalizations were limited to those with varicella listed as the principal discharge 
code.
Characteristics of Varicella-Related Hospitalizations (NHDS)
Age and Gender—The mean overall age of persons discharged after a varicella-related 
hospitalization in NHDS was 22 years (median: 10 years; range: 1 month to 84 years) during 
the 1-dose vaccination era compared with 14 years (median: 6 years; range: 1 day to 99 
years) during the prevaccination era (P < .01). The proportion of varicella hospitalizations in 
persons younger than 10 years decreased over time (Table 1). A greater proportion of the 
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varicella-related hospitalization cases during the 1-dose versus prevaccination eras were 
male (65.6 vs 57.5%; P < .01). This difference was especially pronounced during the 1-dose 
vaccination era among persons aged 0 to 4 years (70.3% male) and 20 and older (69.6% 
male).
Underlying Conditions—The proportion of varicella-related hospitalizations with no 
comorbid or immunocompromising conditions was similar to that in the prevaccination era 
(70.0 vs 70.4%, respectively), whereas the proportion with immunocompromising 
conditions increased from 10.9% in the prevaccination era to 14.4% in the 1-dose 
vaccination era (P < .01) (Fig 3). The proportion of persons with a varicella-related 
hospitalization with ≥1 comorbid medical conditions decreased to 15.3% in the 1-dose 
vaccination era compared with 19.2% in the prevaccination era (P < .01).
Length of Hospitalization—The mean length of varicella-related hospitalization during 
the 1-dose vaccination era was 4.6 days (median: 4 days; range: 1–203 days), corresponding 
to 16 149 days of hospitalization annually. The mean length of hospitalization during the 
prevaccination era was 5.4 days (median: 4 days; range: 1–153 days), corresponding to 56 
975 days of hospitalization annually. As in the prevaccination era, mean length of stay varied 
by health status: during the 1-dose vaccination era, persons with no comorbid or 
immunocompromising conditions had a mean stay of 3.2 days, compared with 6.3 days 
among persons with comorbid conditions (P < .01) and 9.5 days among persons with 
underlying immunocompromising conditions (P < .01).
Complications of Varicella—The numbers of varicella-related complications among 
varicella-related hospitalizations decreased from the prevaccination era such that the 
numbers are now too small to calculate reliable overall and age-specific rates for the 1-dose 
vaccination era. Slightly more than half (54.6%) of varicella-related hospitalization cases 
during the 1-dose vaccination era had ≥1 complication compared with 65.4% during the 
prevaccination era (P < .01). Fluid/electrolyte disturbances were the most frequently 
recorded varicella-related complication followed by pneumonias/lower respiratory infections 
in the 1-dose vaccination era. In contrast, pneumonias/ lower respiratory infections were the 
most frequently recorded varicella-related complication, followed by fluid/electrolyte 
disturbances in the prevaccination era. The mean age of varicella-related hospitalization 
cases with complications varied from 6.6 years among those with skin/soft tissue infections 
to 16.2 years among those with fluid/ electrolyte disturbances, and 18.9 years among those 
with pneumonia/respiratory infections.
NIS
Estimated Number of Varicella Hospitalizations—On the basis of NIS data, an 
estimated total of 27 543 hospitalizations with a varicella discharge diagnosis were 
identified in the United States during the 1-dose vaccination era. Of these, 1713 (6.2%) were 
excluded because of coexistent herpes zoster diagnoses and 7756 (28.2%) as incidental cases 
of varicella. The remaining 18 074 (65.6%) varicella-related hospitalizations correspond to 
an estimated annual average of 2582 [95% CI: 2223–2941]. This represents a 26.2% lower 
number of varicella-related hospitalizations during the 1-dose vaccination era compared with 
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estimates obtained from the NHDS data during the same period, a difference that was 
statistically significant. Of the 18 074 varicella-related hospitalizations estimated from NIS 
data, 14 951 (82.7%) had varicella listed as the principal discharge code, for an average 
annual estimate of 2136 varicella-related hospitalizations using the more restrictive 
definition.
Rates of Varicella Hospitalizations—The overall varicella-related hospitalization rate 
estimated by using NIS for the 1-dose vaccination era was 0.09 per 10 000 population and 
17.0 per 10 000 varicella cases. The rates were 25.0% and 26.4% lower, respectively, than 
NHDS rates and were statistically significantly different. Similar to findings from the NHDS 
data, varicella-related hospitalization rates calculated using NIS data were highest among the 
0 to 4 years age group but decreased by 70.1% when comparing 2000 with 2006 (P < .001). 
Rates for the 20-and-older age group also decreased, by 50% when comparing 2000 with 
2006 (P < .001) (Fig 2).
DISCUSSION
During the 1-dose vaccination era (2000 –2006), varicella-related hospitalization rates 
estimated from the National Hospital Discharge Survey decreased significantly, by 71%. Our 
findings confirm and update trends first suggested by authors of earlier studies in which 
NHDS was used,9,10 studies in which declines in varicella-related hospitalizations from 
1996 to 1999 were reported. Varicella-related hospitalization rates continued to be highest in 
the 0 to 4 years age group but were 72% lower than during the prevaccination era; 
importantly, rates in the 20-and-older age group did not increase after introduction of 
varicella vaccination, and in fact declined 65% during the 1-dose varicella vaccination era. 
Assuming that declines in varicella-related hospitalizations are due, in large part, to the 
routine childhood varicella vaccination program, these data suggest that varicella vaccination 
prevented ~50 000 varicella-related hospitalizations in the United States from 2000 to 2006. 
In addition, the declines in varicella-related hospitalizations have translated to significant 
declines in the direct medical costs for varicella-related hospitalizations since introduction of 
the varicella vaccine in 1995.2,5
Although varicella-related hospitalization rates declined significantly from the 
prevaccination era, rates continued to be highest in the youngest age group (0–4 years). This 
is consistent with other studies in which the effect of varicella vaccination during prevaccine 
and postvaccine introduction has been examined.2,6,17 Numbers were too small to estimate 
rates for the age group of children younger than 1, but overall declines in the 0 to 4 years age 
group likely included declines in the group of children younger than 1. Declines in the group 
of children younger than 1, for whom vaccination is not recommended, would be a result of 
herd immunity provided by the high vaccination coverage in older age groups. Ensuring 
high vaccination coverage among susceptible persons eligible for vaccination (eg, persons 
living with or caring for infants younger than 1) is important for protecting those who cannot 
be vaccinated because they are too young or have contraindications for vaccination.
Concerns have been raised that a universal childhood varicella vaccination program could 
shift varicella disease burden to older persons and result in more severe disease.18,19 In this 
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study, varicella-related hospitalization numbers and rates have actually declined in all age 
groups, including the 10 to 19 and 20-and-older age groups. The mean age of persons 
hospitalized for varicella increased from the prevaccination to the 1-dose vaccination era, 
which is a result of the large decrease in incidence among younger age groups targeted for 
vaccination. Ensuring high varicella vaccination coverage among children and adolescents is 
critical for maintaining low rates of varicella-related hospitalizations while cohorts for 
whom varicella vaccination is recommended age into adulthood, when varicella disease can 
be more severe.20–22 Varicella vaccination school entry requirements for middle school–, 
high school–, and college-aged persons can be an effective tool for achieving high coverage 
in these age groups.1
As the number of varicella-related hospitalizations decreases over time, varicella-related 
complications among hospitalized persons have become so rare that calculations of 
complication rates through NHDS are no longer reliable. Although rare, the bulk of varicella 
complications continue to occur among persons with no comorbid or immunocompromising 
conditions. Similar to findings from the prevaccination era,20,21,23 the most frequently 
reported complications during the 1-dose vaccination era continued to be fluid/electrolyte 
disturbances, skin/ soft tissue infections, and lower respiratory infections (ie, pneumonias).
Varicella vaccination coverage in children aged 19 to 35 months reached 89% in 2006.24 
Despite coverage data being available only for this younger age group, we noted decreasing 
varicella-related hospitalization rates in all age groups during the 1-dose vaccination era. 
The number of varicella-related hospitalizations is expected to continue to decline with 
increasing vaccination coverage because varicella disease in vaccinated persons is generally 
milder than that among the unvaccinated, with fewer lesions and a shorter duration of 
illness.25–27 Data from varicella active surveillance sites showed that during from 1995 to 
2005, among persons with varicella, the rate of hospitalization was two-thirds lower among 
those who were vaccinated compared with those who had not been.6 The data sources used 
in our study lack information on varicella vaccination status for the varicella-related 
hospitalization cases; thus we are unable to compare hospitalization rates between 
vaccinated and unvaccinated persons. Additional assessment of the effect of the varicella 
vaccination program on varicella-related hospitalizations should include monitoring of the 
extent to which hospitalizations are occurring among vaccinated persons.
Our study was subject to several limitations. First, results from analyses of hospital 
discharge codes must be interpreted with caution because diagnostic codes for varicella 
could have been misattributed or inadvertently excluded. It is possible that adults with 
herpes zoster could have been miscoded as varicella; to control for this, we excluded those 
hospitalizations with a coexistent herpes zoster code and analyzed the data by using a stricter 
definition limited to varicella-related hospitalizations with varicella listed as the primary 
diagnosis code. Second, hospital discharge data do not include enough clinical information 
to determine severity of disease and reason for hospitalization. It is possible that 
hospitalization varies by factors other than severity, such as age. Using hospitalizations to 
track changes in severity of varicella over time may be confounded by changing 
hospitalization practices. Finally, because the numbers of varicella-related hospitalizations 
declined greatly during the 1-dose vaccination era, we were limited in the analyses we could 
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perform using NHDS and could not estimate varicella-related hospitalization rates in 
children younger than 1 or age-specific rates of complications.
Analyses of varicella-related hospitalizations using both the NHDS and NIS allow us to 
show that comparable estimates are obtained using the different data sources. We were not 
able to validate varicella-related hospitalizations through examination of medical charts, but 
comparing results from both sources provided a form of validation. The difference between 
the varicella-related hospitalization rates per population from the NHDS and NIS translates 
to ~128 hospitalizations per year or 900 hospitalizations for the 1-dose vaccination era. Both 
data sources are designed to provide nationally representative estimates, so it is unlikely that 
the composition of the hospitals in each source is different enough to explain the differences 
in varicella-related hospitalization rates. Because the difference in estimates between the 2 
surveys is significant, although the trend is similar, the estimates from the NIS, with its 
larger sample size, may be closer to the true estimate for varicella-related hospitalizations. 
As the number of varicella-related hospitalizations continues to decline, the NIS may be a 
better source for evaluating additional trends in varicella-related hospitalizations and 
complications.
CONCLUSIONS
Our analyses of hospital discharge data from the NHDS and NIS provide updates to previous 
analyses of varicella-related hospitalizations and show statistically significant declines in 
varicella-related hospitalizations during the 1-dose vaccination era. The most dramatic 
declines were noted in those age groups targeted for vaccination (<10 years of age), 
suggesting successful impact of the varicella vaccination program. Despite early concerns 
about a shift in age of varicella cases because of the vaccination program,18,19 significant 
declines were also seen in varicella-related hospitalizations among the age group of persons 
aged 20 and older. In 2006, the Advisory Committee on Immunization Practices 
recommended implementation of a routine second dose of varicella vaccine for children with 
the first dose given at 12 to 15 months and the second dose at 4 to 6 years.1 It is expected 
that the implementation of this recommendation will lead to additional declines in varicella 
incidence and hospitalization rates.
ABBREVIATIONS
NHDS National Hospital Discharge Survey
NIS Nationwide Inpatient Sample
ICD-9 International Classification of Diseases, Ninth Revision
CI confidence interval
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WHAT’S KNOWN ON THIS SUBJECT
A number of studies have examined the early impact of the varicella vaccination program 
on varicella-related hospitalizations and have found evidence of decline after vaccine 
implementation.
WHAT THIS STUDY ADDS
This study further documents the continued decline in varicella-related hospitalizations 
during the 1-dose varicella vaccination era and demonstrates statistically significant 
declines of >65% in all age groups. These data suggest that varicella vaccination 
prevented ~50 000 hospitalizations from 2000 to 2006.
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Varicella-related US hospitalizations per 10 000 population from 1988 to 2006 and per 10 
000 varicella cases from 2000 to 2006. Rates were estimated by using data from the NHDS 
and NIS.
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Varicella-related hospitalization rates per 10 000 population according to year and age 
group. Estimates using the NHDS include data from 1988 to 2006 (A), and estimates using 
the NIS include data from 1998 to 2006 (B).
Lopez et al. Page 13














The proportions of varicella-related hospitalizations according to health status and 
vaccination era (before: prevaccination era; 1 dose: 1-dose vaccination era) for each age 
group. Proportions were estimated by using data from the NHDS.
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TABLE 1
Estimated Numbers and Rates of Varicella-Related Hospitalizations per Year According to Age Group During 
the Prevaccination (1988–1995) and 1-Dose Vaccination (2000–2006) Eras, United States









0–4 4724 (44.4) 1376 (39.3) 2.5 0.7
5–9 1731 (16.3) 329 (9.4) 1.0 0.2
10–19 782 (7.4) 386 (11.0) 0.4 0.1
≥20 3394 (31.9) 1407 (40.2) 0.2 0.07
Total 10 632 (100.0) 3498 (100.0) 0.4 0.12
Estimates were calculated by using data from the NHDS.
a
All differences between the prevaccination and 1-dose vaccination eras were statistically significant (P < .001).
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